Interchange Capital Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Interchange Capital Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$443K	Buy	919 +299	+48%	+$139K	0.14%	156
2025 Q4	$281K	Sell	620 -164	-21%	-$70.7K	0.05%	316
2025 Q3	$307K	Sell	784 -268	-25%	-$112K	0.06%	259
2025 Q2	$468K	Sell	1,052 -36	-3%	-$16.6K	0.11%	159
2025 Q1	$527K	Buy	1,088 +52	+5%	+$24.2K	0.15%	134
2024 Q4	$418K	Sell	1,036 -464	-31%	-$215K	0.15%	148
2024 Q3	$698K	Buy	1,500 +107	+8%	+$51.4K	0.25%	106
2024 Q2	$653K	Buy	1,393 +581	+72%	+$252K	0.24%	109
2024 Q1	$359K	Buy	+812	New	+$343K	0.24%	98
2023 Q4	–	Sell	-916	Closed	-$318K	–	162
2023 Q3	$318K	Buy	+916	New	+$320K	0.25%	97
2021 Q1	–	Sell	-331	Closed	-$78K	–	1081
2020 Q4	$78K	Buy	+331	New	+$75.9K	0.04%	338

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Interchange Capital Partners's VRTX Position: Q1 2026 in Review

Interchange Capital Partners increased its Vertex Pharmaceuticals (VRTX) stake by 48% in Q1 2026, buying an estimated $139K and bringing the position to 919 shares worth $443K. The position accounts for 0.14% of the portfolio, ranked #156.

Interchange Capital Partners first reported a position in VRTX in Q4 2020 and has held it in 11 quarters since. The position peaked at $698K in Q3 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Interchange Capital Partners held 919 shares of Vertex Pharmaceuticals worth $443K as of Q1 2026.
Interchange Capital Partners bought 299 Vertex Pharmaceuticals shares in Q1 2026, an estimated $139K.
Vertex Pharmaceuticals made up 0.14% of Interchange Capital Partners's portfolio in Q1 2026, its #156 holding.
Interchange Capital Partners first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 11 quarters since.
Interchange Capital Partners's Vertex Pharmaceuticals position peaked at $698K in Q3 2024.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Interchange Capital Partners's 13F filing for Q1 2026, filed 24 Apr 2026.